Compare Brunswick Corporation (BC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Merck & Co., Inc. — how do they compare? Brunswick Corporation trades at $79.54 (market cap $5.28B), while Merck & Co., Inc. trades at $132.81 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 60.9× Brunswick Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| BC | MRK | |
|---|---|---|
Market Cap | $5.28B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $131.84 |
52-Week Low | $58.75 | $77.60 |
Enterprise Value | $7.28B | $368.53B |
Dividend Yield | 2.16% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brunswick Corporation (BC) trades at $79.54, down 1.11% on the day, with strong analyst support showing 22 buy ratings and a consensus price target of $85.33. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company posted a net loss of $137.3 million in 2025. Technical indicators show a bullish trend with support at $80 and resistance at $82, while fundamentals reveal mixed profitability with negative margins but positive cash flow from operations of $562.1 million.
The outlook remains cautiously optimistic given strong institutional backing and recent earnings beats, though investors face risks from negative profit margins and elevated P/E ratio of 73.92. The stock offers potential upside to analyst targets but requires monitoring of profitability improvements and debt management amid competitive pressures in the marine industry.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
